BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24388871)

  • 1. Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications.
    Kumar J; Ward AC
    Biochim Biophys Acta; 2014 Apr; 1845(2):117-25. PubMed ID: 24388871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of epithelial ovarian cancer cells.
    Zhu X; Shen H; Yin X; Long L; Chen X; Feng F; Liu Y; Zhao P; Xu Y; Li M; Xu W; Li Y
    Oncotarget; 2017 Jun; 8(24):39154-39166. PubMed ID: 28388577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
    Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
    Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    Jia ZH; Jia Y; Guo FJ; Chen J; Zhang XW; Cui MH
    PLoS One; 2017; 12(8):e0183622. PubMed ID: 28859117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
    Colomiere M; Ward AC; Riley C; Trenerry MK; Cameron-Smith D; Findlay J; Ackland L; Ahmed N
    Br J Cancer; 2009 Jan; 100(1):134-44. PubMed ID: 19088723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review).
    Wang SW; Sun YM
    Int J Oncol; 2014 Apr; 44(4):1032-40. PubMed ID: 24430672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-6 trans-signalling induces vascular endothelial growth factor synthesis partly via Janus kinases-STAT3 pathway in human mesothelial cells.
    Yang X; Lin A; Jiang N; Yan H; Ni Z; Qian J; Fang W
    Nephrology (Carlton); 2017 Feb; 22(2):150-158. PubMed ID: 26869278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constitutive activation of STAT3 in breast cancer cells: A review.
    Banerjee K; Resat H
    Int J Cancer; 2016 Jun; 138(11):2570-8. PubMed ID: 26559373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPECT imaging of interleukin-6 receptor in ovarian tumor xenografts with a novel radiotracer of 99mTc-HYNIC-Aca-LSLITRL.
    Li F; Zhang Z; Cheng T; Wei R; Dai Y; Lv M; Luo D; Zhu X; Ma D; Xi L; Dong Q; Ma X
    Amino Acids; 2016 Jan; 48(1):91-101. PubMed ID: 26255282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    Lai SY; Johnson FM
    Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
    Wang S; Zhang W
    Tumour Biol; 2016 May; 37(5):6561-9. PubMed ID: 26638167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
    Kumar J; Fraser FW; Riley C; Ahmed N; McCulloch DR; Ward AC
    Br J Cancer; 2014 Jan; 110(1):133-45. PubMed ID: 24220695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6 as a therapy target in oral squamous carcinoma.
    Culig Z
    Expert Opin Ther Targets; 2013 Jan; 17(1):53-9. PubMed ID: 23101455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory Mechanism of the Outer Membrane Growth of Chronic Subdural Hematomas.
    Osuka K; Watanabe Y; Usuda N; Aoyama M; Iwami K; Takeuchi M; Watabe T; Takayasu M
    J Neurotrauma; 2017 Jun; 34(11):1996-2000. PubMed ID: 28027695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-α expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis?
    Gupta M; Babic A; Beck AH; Terry K
    Hum Pathol; 2016 Aug; 54():82-91. PubMed ID: 27068525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo.
    Zhang X; Liu P; Zhang B; Mao H; Shen L; Ma Y
    Int J Mol Med; 2013 Sep; 32(3):623-8. PubMed ID: 23828376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the IL-6 classic- and trans-signaling pathways in corneal sterile inflammation and wound healing.
    Ebihara N; Matsuda A; Nakamura S; Matsuda H; Murakami A
    Invest Ophthalmol Vis Sci; 2011 Nov; 52(12):8549-57. PubMed ID: 21989726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High mRNA expression level of IL-6R was associated with better prognosis for patients with ovarian cancer: a pooled meta-analysis.
    Chen Q; Xu B; Lan L; Yang D; Yang M; Jiang J; Lu B; Shen Y
    Sci Rep; 2017 Aug; 7(1):8769. PubMed ID: 28821817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.